Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1982 Apr;45(4):552–558. doi: 10.1038/bjc.1982.91

Effect of liposomally trapped antitumour drugs on a drug-resistant mouse lymphoma in vivo

V J Richardson, B E Ryman
PMCID: PMC2010977  PMID: 7073945

Abstract

A TLX-5 mouse lymphoma which was resistant to 1-β-D-arabinofuranosyl cytosine (AraC) was used in vivo to study the possibility of using liposomes as drug-delivery vehicles in order to overcome drug resistance.

The effects of free drugs (AraC, AraCTP and methotrexate) and the liposomally associated drugs on the survival time of tumour-bearing mice were determined.

As a more sensitive measure of cell survival, 125IUdR was incorporated into the DNA of the ascites TLX-5 cells before i.p. injection. Cell survival and the cytotoxic effects of the drugs on the tumour cells were determined by using a double-headed gamma counter to measure the retention of the 125I label.

Both AraC and AraCTP, either as the free drugs or liposomally associated, had no effects on the tumour. Due to the lack of response of tumour cells to these drugs, further studies were initiated with free and liposomally associated methotrexate (MTX), a drug to which the cells were known to be sensitive. It was found that the liposomally associated MTX, at a 5-10-fold lower dose than the free drug, was (a) more effective in prolonging the survival of tumour-bearing mice and (b) as effective as the free drug in killing tumour cells (as measured by the 125I retention).

In vivo MTX was more effective in the liposomally associated form, whereas liposomally entrapped AraC and AraCTP were ineffective. It is proposed that in vivo liposomally associated drugs may be acting not by actively localizing in the tumour cells, but by the liposomes providing a slow-release drug depot, improving the pharmacokinetic properties of MTX.

Full text

PDF
552

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Gregoriadis G., Neerunjun E. D. Treatment of tumour bearing mice with liponsome-entrapped actinomycin D prolongs their survival. Res Commun Chem Pathol Pharmacol. 1975 Feb;10(2):351–362. [PubMed] [Google Scholar]
  2. Juliano R. L., Stamp D. Pharmacokinetics of liposome-encapsulated anti-tumor drugs. Studies with vinblastine, actinomycin D, cytosine arabinoside, and daunomycin. Biochem Pharmacol. 1978 Jan 1;27(1):21–27. doi: 10.1016/0006-2952(78)90252-6. [DOI] [PubMed] [Google Scholar]
  3. Kimelberg H. K., Atchison M. L. Effects of entrapment in liposomes on the distribution, degradation and effectiveness of methotrexate in vivo. Ann N Y Acad Sci. 1978;308:395–410. doi: 10.1111/j.1749-6632.1978.tb22037.x. [DOI] [PubMed] [Google Scholar]
  4. Kobayashi T., Kataoka T., Tsukagoshi S., Sakurai Y. Enhancement of anti-tumor activity of 1-beta-D-arabinofuranosylcytosine by encapsulation in liposomes. Int J Cancer. 1977 Oct 15;20(4):581–587. doi: 10.1002/ijc.2910200416. [DOI] [PubMed] [Google Scholar]
  5. Mayhew E., Papahadjopoulos D., Rustum Y. M., Dave C. Inhibition of tumor cell growth in vitro and in vivo by 1-beta-D-arabinofuranosylcytosine entrapped within phospholipid vesicles. Cancer Res. 1976 Dec;36(12):4406–4411. [PubMed] [Google Scholar]
  6. Mayhew E., Papahadjopoulos D., Rustum Y. M., Dave C. Use of liposomes for the enhancement of the cytotoxic effects of cytosine arabinoside. Ann N Y Acad Sci. 1978;308:371–386. doi: 10.1111/j.1749-6632.1978.tb22035.x. [DOI] [PubMed] [Google Scholar]
  7. Neerunjun E. D., Hunt R., Gregoriadis G. Fate of a liposome-associated agent injected into normal and tumour-bearing rodents: attempts to improve localization in tumour tissues [proceedings]. Biochem Soc Trans. 1977;5(5):1380–1383. doi: 10.1042/bst0051380. [DOI] [PubMed] [Google Scholar]
  8. Papahadjopoulos D., Poste G., Vail W. J., Biedler J. L. Use of lipid vesicles as carriers to introduce actinomycin D into resistant tumor cells. Cancer Res. 1976 Sep;36(9 PT1):2988–2994. [PubMed] [Google Scholar]
  9. Porteous D. D., Munro T. R. The kinetics of the killing of mouse tumour cells in vivo by immune responses. Int J Cancer. 1972 Jul 15;10(1):112–117. doi: 10.1002/ijc.2910100115. [DOI] [PubMed] [Google Scholar]
  10. Rahman Y. E., Hanson W. R., Bharucha J., Ainsworth E. J., Jaroslow B. N. Mechanisms of reduction of antitumor drug toxicity by liposome encapsulation. Ann N Y Acad Sci. 1978;308:325–342. doi: 10.1111/j.1749-6632.1978.tb22033.x. [DOI] [PubMed] [Google Scholar]
  11. Richardson V. J., Curt G. A., Ryman B. E. Liposomally trapped AraCTP to overcome AraC resistance in a murine lymphoma in vitro. Br J Cancer. 1982 Apr;45(4):559–564. doi: 10.1038/bjc.1982.92. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Scherphof G., Roerdink F., Waite M., Parks J. Disintegration of phosphatidylcholine liposomes in plasma as a result of interaction with high-density lipoproteins. Biochim Biophys Acta. 1978 Aug 17;542(2):296–307. doi: 10.1016/0304-4165(78)90025-9. [DOI] [PubMed] [Google Scholar]
  13. Underwood J. C., Carr I. The ultrastructure and permeability characteristics of the blood vessels of a transplantable rat sarcoma. J Pathol. 1972 Jul;107(3):157–166. doi: 10.1002/path.1711070303. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES